ALK and sarcoma: Supporting the latter, exposure of the CD4/NPM-ALK/OT1 mouse to MHV-OVA abrogated ALCL development in favour of hepatocellular carcinomas and sarcoma, as seen in the CD4/NPM-ALK/RAG−/−/OT1 mice [86].